Antipsychotic Lab Monitoring Reference
Atypical (second generation) antipsychotic medications carry known metabolic risks, including weight gain, glucose intolerance, dyslipidemia and hypertension. To mitigate these potential risks, the clinical guidelines recommend baseline and follow-up metabolic monitoring at regular intervals. To aid in monitoring patients using antipsychotic medications, Partners For Kids has collaborated with the Medicaid managed care plans to identify patients who might benefit from receiving updated metabolic labs. Be on the lookout for information regarding antipsychotic lab monitoring in the coming weeks.
For more information, check out monitoring tool.
Published March 2022